

Through Email/ Fax/ Courier

FKOL/SE

October 24, 2013

National Stock Exchange of India Ltd. (NSE)

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East)
Mumbai-400 051
Fax : 022 – 26598237/ 38

Bombay Stock Exchange Ltd. (BSE)

Corporate Relationship Department
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400 001
Fax: 022 – 22723121

Fresenius Kabi Oncology Limited
Echelon Institutional Area, Plot No. 11,
Sector-32, Gurgaon - 122 001,
Haryana, India.
T+91 124 488 5000, +91 124 332 5000
F+91 124 488 5003
www.fresenius-kabi-oncology.com

**Sub: Approval of Unaudited Financial Results for the 2nd Quarter and Half Year
ended September 30, 2013**

Ref: NSE Symbol: FKONCO, BSE Scrip Code: 532545

Dear Sirs,


Please be informed that the Board of Directors of the Company, at its meeting concluded at 2:25 P.M., has approved and taken on record the unaudited Financial Results of the Company for the 2nd Quarter and Half Year ended September 30, 2013, along with the Limited Review Report of the Statutory Auditors thereon, which are being faxed herewith and separately being e-mailed and couriered.

The results are simultaneously being uploaded at the respective online portals of NSE & BSE.

The above is for your information and record and in compliance of Clause 41 of the Listing Agreement with the Stock Exchanges.

Thanking you,

Yours sincerely,
For **Fresenius Kabi Oncology Limited**


Nikhil Kulshreshtha
Company Secretary & Head – Legal

Encl: a/a

Unaudited Financial Results for the Quarter & Half Year Ended 30th September 2013

(Rs. In Lacs)

Part - I

Particulars	Unaudited for the Quarter ended Sep 2013	Unaudited for the Quarter ended June 2013	Unaudited for the Quarter ended Sep 2012	Unaudited for the Half Year ended Sep 2013	Unaudited for the Half Year ended Sep 2012	Audited for the Year ended 31st March 2013
1 Income from operations						
a. Net Sales/Income from Operations (Net of Excise duty)	8,156.41	8,094.61	15,125.88	16,251.02	27,532.34	49,624.62
b. Other operating income	1,458.42	4,592.01	1,327.20	6,050.43	2,270.00	10,005.37
Total Income from operations (net)	9,614.83	12,686.62	16,453.08	22,301.45	29,802.34	59,629.99
2 Expenditure:						
a. (Increase)/decrease in stock in trade & work in progress	(767.10)	114.77	(407.05)	(652.33)	(1,533.04)	(3,101.74)
b. Consumption of raw material	3,504.72	3,558.72	5,370.15	7,063.44	11,114.27	19,173.52
c. Purchase of trading goods	194.91	24.40	46.66	219.31	125.18	424.55
d. Employee cost	2,037.11	1,521.41	1,790.65	3,558.52	3,575.95	7,032.04
e. Depreciation	753.45	690.77	640.19	1,444.22	1,256.40	2,578.62
f. Research & Development	1,220.40	3,783.95	2,043.63	5,004.35	3,782.28	9,503.33
g. Other expenditure	6,313.06	2,835.24	2,808.14	9,148.30	5,703.52	12,298.21
h. Total	13,256.55	12,529.26	12,292.37	25,785.81	24,024.56	47,908.53
3 Profit from operations before other income, interest and exceptional items (1-2)	(3,641.72)	157.36	4,160.71	(3,484.36)	5,777.78	11,721.46
4 Other Income	0.25	85.53	50.26	85.78	98.12	180.10
5 Profit before interest and exceptional items (3+4)	(3,641.47)	242.89	4,210.97	(3,398.58)	5,875.90	11,901.56
6 Finance Charges	731.55	(467.67)	729.20	263.88	718.95	(260.30)
7 Profit after interest but before exceptional items (5-6)	(4,373.02)	710.56	3,481.77	(3,662.46)	5,156.95	12,161.86
8 Exceptional Items	-	-	-	-	-	-
9 Profit (+)/Loss (-) from ordinary activities before tax (7+8)	(4,373.02)	710.56	3,481.77	(3,662.46)	5,156.95	12,161.86
10 Provision for taxation:						
-Current tax	(142.11)	142.11	696.36	-	1,031.39	2,451.00
-Deferred tax	248.55	88.44	89.95	336.99	126.52	971.35
11 Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)	(4,479.46)	480.01	2,695.46	(3,999.45)	3,999.04	8,739.51
12 Extraordinary item (After tax)	-	-	-	-	-	(680.64)
13 Net Profit(+)/Loss(-) for the period (11+12)	(4,479.46)	480.01	2,695.46	(3,999.45)	3,999.04	8,058.87
14 Paid-up equity share capital (face value of Re 1 Each)	1,582.28	1,582.28	1,582.28	1,582.28	1,582.28	1,582.28
15 Reserves excluding revaluation reserves				61,736.32		65,735.77
16 Basic EPS (Excluding Extraordinary item) (in Rs not annualised)	(2.83)	0.30	1.70	(2.53)	2.53	5.52
17 Diluted EPS (Excluding Extra-ordinary items) (in Rs not annualised)	(2.83)	0.30	1.70	(2.53)	2.53	5.52
18 Basic EPS (Including Extra-ordinary items) (in Rs not annualised)	(2.83)	0.30	1.70	(2.53)	2.53	5.09
19 Diluted EPS (Including Extra-ordinary items) (in Rs not annualised)	(2.83)	0.30	1.70	(2.53)	2.53	5.09

Signature



Part II - Information for the Quarter & Half Year Ended 30th September 2013

S.No	Particulars	Unaudited for the Quarter ended Sep 2013	Unaudited for the Quarter ended June 2013	Unaudited for the Quarter ended Sep 2012	Unaudited for the Half Year ended Sep 2013	Unaudited for the Half Year ended Sep 2012	Audited for the Year ended 31st March' 13
A	Particulars of Shareholding						
1	Public Shareholding:						
	-Number of shares	30063255	30063255	15822766	30063255	15822766	30063255
	-Percentage of Shareholding	19	19	10	19	10	19
2	Promoter & Promoter Group Shareholding						
	a) Pledged/Encumbered						
	-Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	Percentage of Share (As % of total shareholding of promoter & promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	Percentage of Share (As % of total share capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non Encumbered						
	-Number of shares	128164400	128164400	142404889	128164400	142404889	128164400
	Percentage of Share (As % of total shareholding of promoter & promoter group)	100	100	100	100	100	100
	Percentage of Share (As % of total share capital of the Company)	81	81	90	81	90	81
B	Investors Complaints						
	Pending at the beginning of the quarter	0					
	Received during the Quarter	0					
	Disposed of during the quarter	0					
	Remaining at the end of the quarter	0					

BS



Unaudited Segmentwise Revenue, Results and Capital Employed for the Quarter & Half Year Ended 30th September 2013

(Rs. In Lacs)

Particulars	Unaudited for the Quarter ended Sep 2013	Unaudited for the Quarter ended June 2013	Unaudited for the Quarter ended Sep 2012	Unaudited for the Half Year ended Sep 2013	Unaudited for the Half Year ended Sep 2012	Audited for the Year ended 31st March 2013
1 Segment Revenue						
A. Formulation	8,347.92	8,357.15	13,033.18	16,705.07	23,823.28	45,224.85
B. Bulk Drug	1,419.49	787.89	7,092.32	2,207.38	13,177.41	19,062.44
C. R&D Service	1,215.14	4,317.34	1,264.23	5,532.48	1,940.13	8,312.74
Total Income from Operations	10,982.55	13,462.38	21,389.73	24,444.93	38,940.82	72,600.03
Less : Inter Segment Revenue	1,367.72	775.76	4,936.65	2,143.48	9,138.48	12,970.04
Net Income from Operation	9,614.83	12,686.62	16,453.08	22,301.45	29,802.34	59,629.99
2 Segment Results (Profit (+) /Loss (-) before tax, interest and unallocable overheads)						
A. Formulation	1,272.59	4,168.04	4,126.58	5,440.63	6,704.09	17,702.63
B. Bulk Drug	(4,752.84)	(3,003.63)	433.78	(7,756.47)	897.78	(1,516.12)
C. R&D Income	163.65	454.22	62.53	617.87	122.78	569.98
Total	(3,316.60)	1,618.63	4,622.89	(1,697.97)	7,724.65	16,756.49
Less : 1) Finance Charges (Unallocated)	(1,174.32)	229.84	189.09	(944.48)	337.54	(38.87)
2) Unallocable Expenditure net off unallocable income	2,230.74	678.23	952.03	2,908.97	2,230.16	4,633.50
Total profit before tax	(4,373.02)	710.56	3,481.77	(3,662.46)	5,156.95	12,161.86
3 Capital Employed (Segment Assets less Segment Liabilities)						
A. Formulation	50,638.91	50,133.21	53,329.57	50,638.91	53,329.57	50,950.35
B. Bulk Drug	18,184.69	17,856.93	21,726.76	18,184.69	21,726.76	19,876.45
C. R&D Service	5,011.22	7,537.54	1,993.50	5,011.22	1,993.50	4,009.98
D. Unallocable Capital Employed	(10,516.22)	(7,729.62)	(13,803.95)	(10,516.22)	(13,803.95)	(7,518.73)
Total Capital Employed	63,318.60	67,798.06	63,245.88	63,318.60	63,245.88	67,318.05

Notes on results for the quarter ended 30th September 2013

- 1 Net Sales for the current quarter is lesser by 46.08% than corresponding previous year quarter contributing to deficit.
- 2 Deficit is attributed to temporary suspension of production of bulk drug unit at Kalyani for technical upgradation, cost thereof being escalated by Rs. 626 lacs during the quarter.
- 3 Other expenditure includes Rs. 2892.48 lacs and Rs. 3013.77 lacs for the quarter and half year ended on 30th Sep 2013 respectively towards professional charges predominantly related to upgradation of Kalyani unit.
- 4 Finance cost for the quarter include Rs 558.45 Lacs on account of exchange loss.
- 5 The figures of earlier periods have been regrouped and reclassified wherever necessary in line with current period grouping.
- 6 The above results have been reviewed by statutory auditors, audit committee and approved by the Board of Directors in the meeting held on 24th Oct. 2013

By Order of the Board
For Fresenius Kabi Oncology Limited

Rakesh Bhargava
Chairman

Gurgaon: 24th October 2013



Statement of Assets and Liabilities as on 30 September 2013

(Rs. In Lacs)

I	EQUITY AND LIABILITIES	As at 30-Sep-13	As at 30-Sep-12
	1. Share holders' Funds		
	a) Share Capital	1,582.28	1,582.28
	b) Reserves and Surplus	61,736.32	61,675.94
	2. Non-current liabilities		
	a) Long Term borrowings	12,420.03	9,522.05
	b) Deferred Tax Liabilities (Net)	2,774.57	1,592.75
	c) Long-term provisions	725.12	942.99
	3. Current Liabilities		
	a) Short-term borrowings	8,266.20	10,043.29
	b) Trade payables	9,358.03	11,474.68
	c) Other current liabilities	4,618.25	4,590.09
	d) Short-term provisions	4,401.23	2,022.06
	Total:	105,884.03	103,446.13
II	ASSETS		
	1. Non-current assets		
	a) Fixed Assets		
	i) Tangible assets	39,560.22	30,056.80
	ii) Intangible assets	407.68	493.75
	iii) Capital work-in-progress	11,877.47	17,383.31
	iv) Plantation in Progress	289.97	199.03
	v) Intangible assets under Development	444.21	666.67
	b) Non-current investments	3.00	3.00
	c) Long-term loans and advances	1,009.32	206.10
	d) Other non-current assets	627.47	463.88
	2. Current assets		
	a) Inventories	24,825.04	22,182.09
	b) Trade receivables	19,838.69	22,896.47
	c) Cash and cash equivalents	101.98	442.35
	d) Short-term loans and advances	6,713.15	6,787.50
	e) Other Current Assets	185.83	1,665.18
	Total:	105,884.03	103,446.13

RB



LIMITED REVIEW REPORT OF THE AUDITOR

To

The Board of Directors,
Fresenius Kabi Oncology Limited

We have reviewed the accompanying statement of unaudited financial results of Fresenius Kabi Oncology Limited for the quarter and half year ended 30th September, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors during meeting dated 24 October 2013. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement

For G. Basu & Co
Chartered Accountants
Firm Registration Number: 301174E



S. Lahiri
Partner

M. No-51717

Place : Gurgaon
Date : 24th October, 2013